Home / Clinics / Metabolic & Weight Loss
Open a Medical Weight Loss Clinic in the Market's Most Talked-About Category.
The GLP-1 wave is real. So is the commoditization risk. The clinic that wins positions itself as a metabolic health partner, not a semaglutide dispenser. ACG builds the one that lasts.
Book a Strategy CallThe GLP-1 Wave Created a Market Opening,
and a Commoditization Risk
Semaglutide and tirzepatide, including Ozempic, Wegovy, Mounjaro, and Zepbound, became the most culturally dominant health topic of the past two years. That consumer demand is real, documented, and still accelerating.
The risk is equally real. The GLP-1 market is flooding with undifferentiated prescribers doing nothing beyond dispensing a medication. The clinic that wins is the one that does more.
ACG builds metabolic clinics that position as metabolic health partners, not semaglutide dispensers. That distinction determines whether a clinic builds a patient relationship or a one-time transaction.
Representative of broader category trends. Local demand varies by market.
What Separates a Metabolic Clinic from
a GLP-1 Vending Machine
Patients on GLP-1 who receive metabolic coaching, body composition tracking, and muscle preservation support get measurably better results and stay enrolled longer. That is the clinic ACG builds.
Semaglutide and tirzepatide protocols prescribed and managed by your Medical Director through an established clinical framework.
Baseline and ongoing metabolic panels positioning the clinic as a comprehensive metabolic health partner, not just a prescriber.
DEXA or bioimpedance tracking that demonstrates real results, muscle retention, fat loss, and progress patients can see.
Metabolic-context peptide adjuncts (such as AOD-9604) and nutrition guidance to prevent the muscle loss that undermines GLP-1 results long-term. For peptide-first clinic models, see our Peptide Therapy page.
Structured dietary support that maximizes GLP-1 outcomes and builds the patient relationship beyond the prescription.
The weight loss patient who gets results is primed for hormone optimization and longevity services within 90 days, natural cross-sell categories ACG can help you add. See our Hormone Optimization and Longevity Clinic pages.
The Compliance Landscape for
Weight Loss Medications
Compounded semaglutide is in active FDA regulatory review. The prescribing landscape for GLP-1 medications is more complex than most first-time clinic owners realize. ACG navigates the current regulatory environment with you.
Weight loss clinic marketing also has specific platform restrictions and claim limitations. ACG builds campaigns that attract patients compliantly.
Pre-vetted partners for semaglutide and tirzepatide, with current eligibility status assessed at launch.
Prescribing MD structure, state licensing requirements, and oversight agreement established before your first patient.
Patient intake, informed consent frameworks, and clinical protocols for GLP-1 management, built before opening.
Platform-specific restrictions and claim limitations addressed, campaigns that generate patient flow without compliance exposure.
ACG keeps clients current on GLP-1 regulatory changes affecting compounding eligibility, prescribing rules, and marketing.
Answers Before
You Open.
Weight loss is the fastest-moving cash-pay vertical right now, and most operator questions are about GLP-1 sourcing, regulatory risk, and how to compete in a market that's getting crowded. Honest answers below.
If something isn't covered here, that's what the consultation is for. No pressure, no pitch.
View All FAQsWith GLP-1 medications so popular, is the weight loss market already saturated?
What's required to legally offer compounded GLP-1 medications?
What if the FDA changes compounding regulations and shuts down compounded GLP-1?
What's the realistic patient volume in the first 6 months?
Should I offer monthly programs, single treatments, or both?
Do weight loss patients require ongoing labs and monitoring?
What's the staffing structure for a weight loss clinic?
The Window Is Open.
The Market Is Already Moving.
Book a free strategy call. ACG will walk you through the metabolic and weight loss opportunity in your specific market, the compliance picture, the differentiation strategy, and what the process looks like.
Book a Strategy CallFree 30-minute call · No pitch · ACG works with a select number of clients at any given time
Structured to keep you on the right side of the line.
Regenerative health is one of the most heavily scrutinized spaces in medicine. Knowing the rules is not a footnote to what we do. It is the foundation. Here is how we structure every clinic we help launch.
Your Medical Director Directs Care
You own and operate the business. Every clinical, prescribing, and treatment decision is made by an independent, state-licensed Medical Director, structured to respect Corporate Practice of Medicine laws in your state. We connect you to a vetted network; you retain your own provider.
We Know the Regulatory Lines
PRP, peptides, GLP-1 medications, and cellular products each carry their own federal and state rules, and not every product or use is FDA-approved. Some, like exosomes for therapeutic use, are not FDA-approved at all, and we steer you away from them. We help you build a treatment menu on defensible, compliant options and a marketing approach that holds up to FDA, FTC, and state medical board scrutiny.
No Hype. No Guarantees.
We show you real ranges, not fantasy numbers, and we never promise an income or a clinical outcome. What you earn depends on your market, your capital, and your execution. We would rather set honest expectations than sell you a dream.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe, or sell any drug, biologic, device, or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the regulatory compliance of every product, therapy, and claim. See our full regulatory notice below.